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Abstract
The majority of HIV-1 elite controllers (EC) restrict HIV-1 replication through highly function-
al HIV-1-specific T cell responses, but mechanisms supporting the evolution of effective
HIV-1-specific T cell immunity in these patients remain undefined. Cytosolic immune recog-
nition of HIV-1 in conventional dendritic cells (cDC) can facilitate priming and expansion of
HIV-1-specific T cells; however, HIV-1 seems to be able to avoid intracellular immune rec-
ognition in cDCs in most infected individuals. Here, we show that exposure of cDCs from
EC to HIV-1 leads to a rapid and sustained production of type I interferons and upregulation
of several interferon-stimulated effector genes. Emergence of these cell-intrinsic immune
responses was associated with a reduced induction of SAMHD1 and LEDGF/p75, and an
accumulation of viral reverse transcripts, but inhibited by pharmacological blockade of viral
reverse transcription or siRNA-mediated silencing of the cytosolic DNA sensor cGAS. Im-
portantly, improved cell-intrinsic immune recognition of HIV-1 in cDCs from elite controllers
translated into stronger abilities to stimulate and expand HIV-1-specific CD8 T cell re-
sponses. These data suggest an important role of cell-intrinsic type I interferon secretion in
dendritic cells for the induction of effective HIV-1-specific CD8 T cells, and may be helpful
for eliciting functional T cell immunity against HIV-1 for preventative or therapeutic
clinical purposes.
Author Summary
Elite controllers (EC), a small group of HIV-1-infected individuals that are able to control
viral replication in the absence of antiretroviral therapy, provide living evidence that the
human immune system is able to spontaneously control HIV-1 infection and serve as a
model for inducing a functional cure of HIV-1 infection in broader patient populations.
Prior studies indicated that T cell-mediated immune responses represent the backbone of
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effective antiviral immune defense in EC; however, emerging studies suggest that innate
and cell-intrinsic immune activities may have critical roles for supporting and enhancing
HIV-1-specific T cells. Here, we performed a detailed investigation of conventional den-
dritic cells (cDC) from elite controllers and their responses to HIV-1 infection. These stud-
ies indicate that cDC from EC have improved abilities to sense cytosolic HIV-1 replication
products, and can more effectively mount cell-intrinsic type I interferon (IFN) secretion in
response to HIV-1 infection. Notably, such increased production of type I IFN in response
to viral antigen translated into enhanced abilities to prime and expand HIV-1-specific T
cells. Together, these data suggest that a fine-tuned interplay between innate dendritic cell
responses and adaptive HIV-1-specific CD8 T cells represents a critical component of an-
tiviral immune defense in elite controllers.
Introduction
Elite controllers can maintain undetectable levels of HIV-1 viral replication in the absence of
antiretroviral therapy, at least in part through the generation of highly-efficient HIV-1-specific
T cell responses [1–4]. As such, these patients provide living evidence that in principle, the
human immune system is capable of generating a T cell-mediated immune response that al-
lows to effectively controlling HIV-1 replication. However, it is uncertain why such immune
responses occur only in very few patients, and what mechanisms support the development of
highly-effective T cell immune responses in such a small number of individuals, and not in the
majority of alternative individuals. Dendritic cells (DCs) represent the most effective naturally-
occurring antigen-presenting cells and have critical roles for inducing and maintaining anti-
gen-specific T cell responses [5–10]. However, specific functional characteristics of DCs that
are instrumental in generating protective HIV-1-specific T- cell responses in elite controllers
are unclear, and represent an understudied area of investigation. Understanding the mecha-
nisms that facilitate the induction of effective HIV-1-specific T cells by dendritic cells is of criti-
cal interest for developing improved immunologic approaches for HIV-1 treatment and
prevention, specifically since most HIV-1 vaccine candidates rely on dendritic cells for induc-
ing HIV-1-specific immune responses.
Human cells have the ability to respond to viral infections by cell-intrinsic immune re-
sponses that lead to secretion of type I interferons (IFN-I) and upregulation of a wide panel of
IFN-stimulated genes (ISG) with antiviral effector functions [11,12]. This cell-intrinsic im-
mune response is extremely effective in defending the host against a panel of different viruses
[13], but early reports suggested that human cells are unable to mount such immune responses
against HIV-1 [14,15]. However, recent discoveries have shown that human conventional DCs
(cDC) are generally capable of generating IFN-I responses to HIV-1, but HIV-1 seems to be
able to escape from such cell-intrinsic immunity in most patients [16–18]. A dominant mecha-
nism that may allow HIV-1 to avoid cell-intrinsic immune responses in cDC includes the ex-
pression of SAMHD1, a host protein that can block HIV-1 reverse transcription by
hydrolyzing dNTPs [19–22] or inhibit HIV-1 RNA through direct degradation [23]. In the
presence of experimental SAMHD1 knockdown, viral replication in host cells progresses be-
yond the level of reverse transcription, and viral reverse transcripts or proteins can be sensed
by host molecules that can initiate secretion of type I interferons [16,24–27]. In this way, re-
striction of HIV-1 replication by SAMHD1 may paradoxically benefit the virus more than the
host, which likely explains why SAMHD1 represents the only effective HIV-1 restriction factor
that HIV-1 does not neutralize through the activity of accessory proteins [28]. In addition to
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SAMHD1, cell-intrinsic immune responses in DCs are inhibited by the host protein TREX1, a
host exonuclease that degrades HIV-1 reverse transcripts, which otherwise trigger microbial
DNA sensors, leading to cell-intrinsic secretion of type I interferons [18,29].
In the present study, we demonstrate that unlike chronic progressors, dendritic cells from
elite controllers have the ability to effectively mount cell-intrinsic type I IFN secretion in re-
sponse to HIV-1 infection, likely through an accumulation of viral reverse transcripts that
serve as substrates for the cytosolic DNA sensor cGAS (cyclic guanosine monophosphate-
adenosine monophosphate (GMP-AMP) synthase). Recognition of these early viral replication
products in elite controllers seemed to be facilitated by an enhanced upregulation of cGAS, led
to rapid and sustained secretion of type I IFNs, and was functionally relevant for supporting ef-
fective HIV-1-specific CD8 T cell responses. Together, these results suggest previously unrec-
ognized innate mechanisms of HIV-1 immune recognition that contribute to T cell-mediated
immune control of HIV-1.
Results
Exposure to HIV-1 induces rapid maturation and sustained type I IFN
secretion in conventional DCs from elite controllers
To determine whether human primary cDCs from EC are capable of mounting cell-intrinsic
type I IFN responses against HIV-1, we conducted ex-vivo infection experiments with PBMC
from different study cohorts with a GFP-encoding VSV-G pseudotyped HIV-1 virus causing
single rounds of viral infections [16]; this viral construct infects cells independently of viral cor-
eceptor-mediated entry processes, but can be intracellularly sensed in a similar way as R5-trop-
ic primary HIV-1 isolates [27]. At 24 and 48 hours after infection, cDCs were isolated from
PBMC, and subjected to gene expression analysis. Cells from untreated, chronically HIV-1-in-
fected patients (CP), HIV-1-infected patients receiving suppressive antiretroviral therapy
(HAART) and HIV-1-uninfected persons were used for comparison. These experiments dem-
onstrated that upon exposure to HIV-1, IFNα and IFNβmRNA expression was rapidly and
significantly upregulated at 24 hours post-infection (p.i.) in cDCs from EC; these elevated levels
were sustained at 48h p. i. (Fig 1A). Exposure to control viral preparations (generated by trans-
fection of the viral producer cell line with salmon sperm DNA instead of the HIV-1 plasmid)
failed to induce type I IFN responses. In contrast to cDC from EC, upregulation of IFNα/β ex-
pression in cDC from HIV-1 negative persons was delayed and was not detectable at statistical-
ly significant levels until 48h p.i.. IFNα expression in cDCs from HAART-treated patients after
HIV-1 exposure was only transiently induced at 24 hours p.i. (Fig 1A); IFNβ expression was
barely affected by HIV-1 infection in this cohort. In untreated CP, baseline levels of IFNα/β in
cDCs were slightly elevated in comparison to alternative patients, but did not increase substan-
tially upon HIV-1 exposure, neither at 24 hours nor 48 hours p. i.
We subsequently analyzed the surface expression of costimulatory molecules and activation
markers on cDCs after HIV-1 infection. We observed that the rapid and sustained upregulation
of type I IFN expression in cDCs from EC after HIV-1 infection was associated with a signifi-
cantly increased surface expression of CD86, CD83 and CD40 at 24 hours p.i., which reached lev-
els otherwise observed after stimulation of cDC with the TLR3 ligand Poly(I:C) (Fig 1B and S1
Fig). cDCs from all the alternative study cohorts also upregulated costimulatory molecules and
maturation markers at 48 hours after infection, indicating that they were capable of responding
to the virus, but induction of these molecules was delayed in comparison to cDC from EC (S1B
Fig). Addition of exogenous IFNβ to the media culture induced the expression of costimulatory
molecules in a dose-dependent manner (S1C Fig) and rescued the cDCmaturation defect ob-
served in CP and HAART patients (S1D Fig). In addition, we observed that the expression
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intensity of 28 interferon-stimulated effector genes (ISG) was upregulated in cDC at 48 hours
post-infection; this occurred in all patient cohorts, but was most strongly and consistently notice-
able in cDC from EC, despite some heterogeneity within this group (S1 and S2 Tables and Fig
1C) [30]. Induction of most ISGs in cDCs from ECs occurred in a highly interconnected and co-
ordinated fashion, while expression of individual ISG in CP and HIV-1 negative persons were
more weakly correlated, and exhibited opposing increases and decreases for certain groups of
transcripts (Fig 1D). Together, these findings demonstrate a unique kinetic profile of activation,
maturation and IFN secretion in cDCs from EC after exposure to HIV-1, and suggest that cDCs
Fig 1. Type I IFN secretion and activation in cDCs after ex-vivo exposure to HIV-1. (A): IFNα and IFNβmRNA levels in isolated BDCA1+ cDCs from HIV-
negative persons (Neg), individuals with chronic progressive HIV-1 infection (CP), Elite controllers (EC) and HAART-treated HIV-1 patients (HAART) at 24
and 48 hours after exposure to HIV-1 (HIV) or to media only (Med) as negative control. Horizontal lines represent the median for each specific cohort and
experimental condition. (B): Mean Fluorescence Intensity (MFI) reflecting surface expression of CD86, CD83 and CD40 in cDCs from the different study
cohorts at 24 hours after infection with HIV-1 (HIV) or after exposure to poly(I:C) (PIC). MFI values are expressed as fold-changes in comparison to baseline
levels. Intra-individual differences were tested for statistical significance usingWilcoxon matched-pairs signed rank tests (above each cohort), differences
between cohorts were tested using a Kruskal-Wallis test with post-hoc Dunn’s test; * p<0.05; ** p<0.01; *** p < 0.001; **** p< 0.0001. Horizontal lines
represent the median for each specific cohort and experimental condition. (C): Heatmaps reflecting gene expression patterns of 28 interferon-stimulated
genes (ISG) in cDCs from Neg (n = 6), CP (n = 6) and EC (n = 6) at 48 hours after infection with HIV-1. (D): Heatmaps reflecting correlations among gene
expression intensities of all 28 ISGs in indicated study cohorts. Color-coding reflects Pearson’s correlation coefficient indicating strengths of statistical
association between expression intensities of given gene pairs.
doi:10.1371/journal.ppat.1004930.g001
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from EC differ from those of other patients by their ability to mount rapid and sustained cell-in-
trinsic secretion of IFNα/β in response to HIV-1.
Accumulation of HIV-1 RT products in cDCs from EC
To explore the underlying reasons for the ability of cDCs from EC to mount early and strong
cell-intrinsic immune responses upon HIV-1 infection, we subsequently analyzed HIV-1 repli-
cation steps in cDCs from the different patient cohorts. In agreement with previous reports
[16], productively infected cells were hardly detected in primary cDCs during the first 48 hours
after exposure to HIV-1 (Fig 2A and 2B), irrespectively of the patient cohorts. Such resistance
to HIV-1 was also observed in monocyte-derived DC from HIV-1 negative persons (S2A Fig),
as reported previously [16]. However, we noted significant proportions of GFP-expressing,
HIV-1 positive cells in primary cDCs from HIV-negative persons at 96 hours p.i. (Fig 2B and
2C) when MDDC continued to resist productive HIV-1 infection (S2A Fig). Thus, consistent
with previous studies [31–33], our data indicate that primary cDCs from HIV-1 negative sub-
jects are capable of supporting HIV-1 replication, at least after prolonged periods of incuba-
tion. Interestingly, cDCs from both CP and HAART-treated patients displayed substantially
reduced susceptibility to productive infection (Fig 2B and 2C). Remarkably, cDCs from EC
also seemed less susceptible to HIV-1 infection than cDCs from healthy individuals, but a
trend towards higher proportions of infected cells (Fig 2C) and higher per-cell levels of GFP ex-
pression (Fig 2D) were found in cells from these patients compared to CP and HAART individ-
uals. Similar results were obtained using a CCR5-tropic GFP-encoding HIV-1 virus, although
as expected, efficiency of infection was lower than with the VSV-G-pseudotyped HIV-1 virus
(S2B and S2C Fig). Importantly, differential susceptibility of cDCs from each cohort to infec-
tion with HIV-1 was not associated with significant differences in cell viability among the
study groups (S2D Fig). Together, our findings indicate that primary cDCs can be productively
infected with HIV-1 in vitro and paradoxically suggest that cDCs from EC subjects are more
susceptible to de novo infection with HIV-1 than CP and HAART patients.
We next analyzed early steps of viral replication in primary cDCs from our study cohorts at
48 hours p.i.. Notably, despite significantly lower levels of productive HIV-1 infection in cDCs
from EC compared to HIV-1 negative individuals, cDCs from EC contained similar levels of
both early and late reverse transcripts and 2-LTR circles as those from HIV-1 negative individ-
uals; however, in comparison to cDCs from CP and HAART-treated patients, RT products and
2-LTR circles were significantly elevated in cDC from EC (Fig 3A). Importantly, such differ-
ences in HIV-1 RT product concentrations among the different study cohorts were already evi-
dent at 24h p.i. (S3 Fig). In contrast, no significant difference was found in levels of integrated
HIV-1 DNA in cDCs from EC in comparison to other study cohorts (Fig 3B). These data re-
sulted in significantly increased ratios of late RT transcripts and 2-LTR DNA to integrated
HIV-1 DNA in EC compared to CP and HAART-treated cohorts, consistent with a dispropor-
tionate accumulation of RT products in cDCs from EC relative to other study cohorts (Fig 3C).
Therefore, our data suggest that elevated levels of viral RT products present in cDCs from EC
might facilitate cell-intrinsic viral recognition and lead to enhanced production of type I IFNs
in response to HIV-1. To test whether type I IFN responses were in fact dependent on the pres-
ence of HIV-1 RT products, we infected cDCs from EC with HIV-1 in the presence or absence
of antiretroviral drugs inhibiting either early or late steps of HIV-1 reverse transcription or
viral DNA integration. As shown in Fig 3D, pharmacological inhibition of HIV-1 reverse tran-
scription dramatically reduced the expression of type I IFNs in primary cDCs. In contrast, inhi-
bition of HIV-1 integration had only a modest effect on the expression of type I IFNs that did
not reach statistical significance. Overall, these findings indicate distinct viral replication
Cell-Intrinsic Immunity to HIV in Dendritic Cells
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patterns in cDCs from EC that lead to a relative accumulation of RT products in cDCs, and are
associated with a more effective induction of cell-intrinsic type I IFN responses.
Weak induction of SAMHD1 and LEDGF/p75 in cDCs from EC
We hypothesized that altered expression patterns of intracellular host proteins might be re-
sponsible for the accumulation of HIV-1 RT products observed in cDCs from EC. To investi-
gate this, we first analyzed the expression of SAMHD1 and TREX1 in cDCs after exposure to
HIV-1; these host factors can affect HIV-1 RT products by reducing the synthesis of HIV-1 RT
Fig 2. Susceptibility of primary cDCs to ex-vivo infection with HIV-1. (A): Flow cytometry gating strategy
for defining cDCs in bulk PBMC cultures. (B): Representative flow cytometry dot plots indicating GFP
expression in gated CD11c+ HLA-DR+ cDCs from Neg, CP, EC and HAART individuals after 24, 48 and 96
hours of ex-vivo infection with GFP-encoding HIV-1. Numbers in dot plots reflect the proportion of GFP-
positive cells within gated cDCs. (C–D): Proportion (C) and GFPMFI (D) of GFP+ cDCs from Neg, CP, EC
and HAART subjects at 96 hours after infection with HIV-1 (n = 20 tested subjects for each cohort). Horizontal
lines represent the median for each specific cohort and experimental condition. Differences among cohorts
were tested using a Kruskal-Wallis test with post-hoc Dunn’s test (* p<0.05; *** p<0.001) or using Mann
Whitney U test (# p<0.05; ## p<0.01).
doi:10.1371/journal.ppat.1004930.g002
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products [19–22] or enhancing their degradation [18,29], respectively. Basal mRNA expression
levels of SAMHD1 and TREX1 were not significantly different in cDCs from the different pa-
tient cohorts, although a tendency for higher expression was detected in cDCs from HIV-1-in-
fected patients (Fig 4A and 4B). However, after 48 hours of exposure to HIV-1, only cDCs
from HIV-1 negative study persons, HAART and CP significantly induced the transcription of
SAMHD1, while cDC from ECs displayed largely similar mRNA levels of SAMHD1 as unin-
fected cDCs (Fig 4A). Importantly, similar patterns of SAMHD1 protein expression were also
observed when cDCs were isolated prior to exposure to HIV-1 (S4A and S4B Fig). Notably,
siRNA-mediated downregulation of SAMHD1 in ex-vivo infected cDCs led to an accumulation
Fig 3. HIV-1 replication patterns in cDCs from EC. (A): Early and late HIV-1 reverse transcripts (RT) and 2-LTR circles in cDCs from indicated study
subjects at 48 hours after ex vivo infection with HIV-1. (B): Analysis of integrated HIV-1 DNA in primary cDCs from the different study cohorts. Basal levels of
integrated HIV-1 DNA are shown in the left panel, right panel shows de novo HIV-1 integration in cDCs after subtraction of baseline levels of integrated HIV-1
DNA. (C): Analysis of late HIV-1 RT products and 2-LTR circles normalized to levels of de novo integrated HIV-1 DNA in cDCs at 48 hours after infection. (A–
C): Differences between different cohorts were tested for statistical significance using a Kruskal-Wallis test with post-hoc Dunn’s test or using MannWhitney
U test (# p<0.05; ## p<0.01). (A,B,C). Horizontal lines represent the median for each specific cohort and experimental condition. (D): Inhibition of IFNα and
IFNβmRNA expression in cDCs from EC cultured in media (Med) or infected with HIV-1 (HIV) in the presence or absence of AZT, Efavirenz (EFV) or
Raltegavir (Ral). Data reflect mean and standard error from qPCR values of IFNα and IFNβmRNA levels after normalization to β-actin endogenous
expression from n = 5 experiments. Numbers above bars represent the mean percentage of inhibition induced by each drug. Differences were tested for
statistical significance using a one-tailed Wilcoxon matched-pairs signed rank test, * p<0.05.
doi:10.1371/journal.ppat.1004930.g003
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Fig 4. Expression of host restriction factors in cDCs from EC. (A) SAMHD1 mRNA expression levels in
cDCs from Neg (n = 11), CP (n = 11), EC (n = 11) and HAART-treated (n = 11) subjects at 48 hours after
exposure to HIV-1 (HIV) or to media only (Med). (B): mRNA levels of TREX1 in cDCs from Neg (n = 11), CP
(n = 11), EC (n = 11) and HAART (n = 11) individuals at 48 hours after exposure to HIV-1 (HIV), or to media
only (Med). (A–B): Horizontal lines represent the median for each specific cohort and experimental condition.
(C): Efficiency of siRNA-mediated SAMHD1 protein knock-down in primary cDCs 24h after treatment with
scramble (SC) or SAMHD1-specific (SAM) siRNAs. Left panel shows a representative western blot analysis
of SAMHD1 and β-actin expression on cDCs, right panel represents cumulative SAMHD1 expression data
after normalization to β -actin in DCs nucleofected with SC (blue; n = 4) or SAM (brown; n = 4) siRNAs. The
number above the bar represents the mean inhibition (%) in SAMHD1 protein expression after treatment with
specific siRNAs. (D): Relative expression of early (left panel) and late (right panel) HIV-1 reverse transcripts
in cDCs after ex vivo infection in the presence or absence of siRNA-mediated SAMHD1 silencing. Statistical
significance was calculated using a Wilcoxon matched-pairs signed rank test. (E-F): mRNA levels of TPNO3
(E) and LEDGF/p75 (F) in cDCs from the indicated study cohorts at 48 hours after exposure to HIV-1 (HIV), or
to media only (Med). Differences within cohorts were calculated using a Wilcoxon matched-pairs signed rank
test * p<0.05; ** p<0.01; *** p<0.001. (D-E-F): Horizontal lines represent the median for each specific
cohort and experimental condition.
doi:10.1371/journal.ppat.1004930.g004
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of late RT products (Fig 4C and 4D). With the exception of HAART-treated patients, expres-
sion levels of TREX1 were significantly increased in cDCs from all other study cohorts after
HIV-1 exposure, although this was less obvious in cDCs from EC (Fig 4B). Together, these
data suggest that a weaker induction of SAMHD1, and possibly of TREX1, might facilitate
HIV-1 replication and contribute to accumulation of HIV-1 RT products in cDCs from EC
after ex vivo infection.
Since the efficiency of HIV-1 DNA integration may also affect the described accumulation
of HIV-1 RT products in cDCs from EC, we subsequently analyzed transcriptional levels of
host proteins supporting HIV-1 integration, such as [34–36] TPNO3 [37,38] and LEDGF/p75
[39,40]. As shown in Fig 4E, a significant increase in the amounts of TPNO3 transcripts was
observed in cDCs from all patient cohorts after exposure to HIV-1. In contrast, LEDGF/p75
mRNA expression remained essentially unchanged in cDCs from EC, as opposed to cDCs
from the other three patient cohorts in which upregulation of LEDGF/p75 occurred; this sug-
gests that ineffective LEDGF/p75-dependent HIV-1 DNA integration in cDCs from EC may
also contribute to an accumulation of RT transcripts that cannot effectively integrate into chro-
mosomal DNA (Fig 4F). Thus, these data indicate that cDCs from EC have unique expression
profiles of host factors relevant for shaping and structuring the HIV-1 replication cycle, and
suggest that a weak induction of the host restriction factor SAMHD1, and possibly TREX1 and
LEDGF/p75, in cDCs from EC may play an important role for a relative accumulation of viral
reverse transcripts in cDCs from such patients.
Cell-intrinsic type I IFN secretion in primary cDCs depends on cGAS
We next investigated specific sensors of microbial DNA that may be involved in enhanced cell-
intrinsic type I IFN secretion in response to HIV-1 infection in primary cDCs from EC. For
this purpose, expression of cytosolic DNA sensors was analyzed at 24 and 48 hours after infec-
tion of cDCs from different patient cohorts with HIV-1. Interestingly, we observed that the ex-
pression of cGAS, a recognized sensor for HIV-1 DNA in monocyte-derived DC [27,41,42],
was more efficiently upregulated in cDCs from EC shortly after infection, but expression levels
in alternative patients approached those of EC after 48 hours p.i. (Fig 5A). Interestingly, the ex-
pression of STING, a downstream effector of the DNA sensor cGAS [43], was also significantly
induced in cDCs from EC at 24 hours p.i. (Fig 5A). Expression of IFI16, a DNA sensor impor-
tant for the cell-intrinsic recognition of HIV-1 DNA in CD4 T cells [44–46], was similarly in-
duced in cDCs from all cohorts at 24 hours p. i. (Fig 5A). Interestingly, expression of STING
continued to increase at 48 hours in EC, but remained largely stable in the other study patient
cohorts (Fig 5A). Since STING expression is sensitive to type I interferons, its continuous in-
duction in cDCs from EC may result from stronger cell-intrinsic secretion of IFNα/β described
above. Importantly, induction of STING and cGAS appeared to be positively correlated with
upregulation of IFNβ at 48 hours p.i. on cDCs (S5A Fig), suggesting an important role of these
molecules in cytoplasmic HIV-1 immune recognition. To better define the role of cGAS for the
induction of type I IFN responses in cDCs from EC, we analyzed changes of type I IFN expres-
sion in HIV-1-infected primary cDCs after siRNA-mediated downregulation of cGAS expres-
sion. As shown in Fig 5B, silencing of cGAS (S5B and S5C Fig) drastically impaired the
induction of both IFNα and IFNβ secretion in response to HIV-1 infection. These effects were
not associated with changes in cell viability (S5B Fig) or an inability to respond to other stimuli
such as Poly I:C (S5D Fig) in cDCs. Overall, these data suggest that the HIV-1 DNA sensor
cGAS is preferentially upregulated in cDCs from EC, and facilitates a more rapid and efficient
recognition of cytoplasmic HIV-1 DNA, leading to more potent cell-intrinsic IFN secretion in
these cells.
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Cell-intrinsic immune responses in cDCs from EC support HIV-1-specific
T cells
We sought to determine whether more efficient cell-intrinsic immune responses against HIV-1
in cDCs from EC can result in improved abilities to stimulate antigen-specific T cells. For this
purpose, we first tested the ability of uninfected and HIV-1-infected cDCs from the different
study cohorts to induce proliferation of CFSE-labeled allogeneic CD4+ and CD8+ T cells. As
shown in Fig 6A, 6B and 6C, HIV-1-infected cDCs from EC had significantly elevated abilities
to induce proliferation of allogeneic CD4+ and CD8+ T cells after 6 days in culture, compared
Fig 5. Induction of cytosolic DNA sensors in cDCs from EC. (A): Fold change in cGAS, STING and IFI16
mRNA expression levels in indicated study cohorts at 24 (upper panels) and 48 (lower panels) hours after ex-
vivo infection with HIV-1. Induction of mRNA expression in comparison to baseline levels was tested for
statistical significance using Wilcoxon matched-pairs signed-rank test tests. Significant differences between
distinct cohorts were calculated using a MannWhitney test. No correction for multiple comparisons was
applied (B): IFNα and IFNβ expression in primary cDCs nucleofected with scrambled (SC) or cGAS-specific
siRNAs, followed by infection with HIV-1. Data from n = 4 experiments are shown. Data were normalized to
results from experiments with scrambled siRNA sequences. Differences in type I IFN responses between
untreated or SC- or cGAS-nucleofected cDCs were tested for statistical significance using a Kruskal-Wallis
test with post-hoc Dunn’s test * p<0.05; ** p<0.01.
doi:10.1371/journal.ppat.1004930.g005
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Fig 6. Antigen-presenting properties of cDCs after exposure to HIV-1. (A): Representative flow
cytometry plots reflecting proliferation of CD4+ T cells after stimulation with allogeneic uninfected (Med) or
HIV-1 infected (HIV) cDCs from Neg, CP, EC and HAART patients. Numbers in flow cytometry plots
represent the proportion of proliferating CFSElow T cells. (B–C): Induction of allogeneic CD4 (B; n = 8) and
CD8 T (C; n = 7) cell proliferation after exposure to HIV-1 infected cDC from indicated study cohorts.
Horizontal lines represent the median for each specific cohort and experimental condition. (D):
Representative flow cytometry dot plots reflecting IFN-γ secretion in an HLA-A2-SL9 (SLYNTVATL)-specific
CTL cell line after 16 hours of co-culture with uninfected or HIV-1-infected cDCs from Neg, CP, EC and
HAART individuals. (E): Proportion of IFNγ+ cells in the SL9 CTL cell line after exposure to HIV-1-infected
cDCs from indicated study groups. Cumulative data from n = 8 experiments are shown. (B,C,E): Differences
within and among study groups were tested for statistical significance using a Wilcoxon matched-pairs
signed-rank test rank test or a MannWhitney test corrected for multiple comparisons using Bonferroni
method, respectively. * p<0.05; ** p<0.01. (F): Induction of allogeneic CD4 (left; n = 7) and CD8 (right; n = 7)
T cell proliferation after exposure to cDC from EC cultured in the presence of media (Med) or infected with
HIV-1 in the presence or absence of AZT or RAL. Statistical significance of differences was tested using a
Wilcoxon matched-pairs signed rank test. Bonferroni correction was applied for multiple comparisons.*
p<0.05. (E-F): Horizontal lines represent the median for each specific cohort and experimental condition.
doi:10.1371/journal.ppat.1004930.g006
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to HIV-1-infected cDCs from alternative study subjects. To confirm these findings with CD8+
T cells specific for HIV-1, we cultured a cytotoxic T cell (CTL) clone that recognizes the immu-
nodominant HIV-1 Gag peptide SLYNTVATL restricted by HLA02:01 [47] in the presence of
unstimulated or HIV-1-infected cDCs from HLA-matched study subjects. As shown in Fig 6D
and 6E, HIV-1-infected cDCs from EC were able to elicit significantly more IFNγ secretion in
HIV-1-specific CD8+ T cells, in contrast to cDCs from chronic progressors or HAART-treated
individuals which promoted significantly less efficient IFNγ secretion. Therefore, our results
indicate that upon HIV-1 infection, cDCs from EC acquire improved antigen-presenting prop-
erties and have increased abilities to stimulate HIV-1-specific T cells. Importantly, improved
antigen-presenting properties of cDCs from EC after infection with HIV-1 were abrogated by
pharmacological inhibition of HIV-1 reverse transcription, but not by inhibition of HIV-1 inte-
gration, consistent with our previous identification of viral reserve transcripts as the main viral
substrate required for inducing cell-intrinsic immune responses (Fig 6F). Together, these data
suggest an important contribution of innate, cell-intrinsic immune recognition of HIV-1 in
cDCs to the generation of potent antiviral T cell immune responses in elite controllers.
Discussion
Cell-intrinsic secretion of type I IFN represents an efficient antimicrobial immune defense
strategy, but the clinical significance of these types of immune responses against HIV-1 re-
mains uncertain. Recent studies show that in principle, human cells have the ability to respond
to HIV-1 infection with increased secretion of type I interferons; however, several negative reg-
ulators of IFN secretion seem to actively prevent these immune responses in most patients
[48–50]. In this study, we have conducted a detailed analysis of cell-intrinsic immune responses
to HIV-1 in primary dendritic cells from elite controllers, a small subgroup of patients who
control HIV-1 replication in the absence of treatment and arguably represent the best patients
for detecting effective immune defense mechanisms against HIV-1 disease progression. Our
data indicate that cDCs from EC differed from those of other patients by cell-intrinsic type I
IFN secretion that occurred rapidly and sustainably after HIV-1 infection, was associated with
increased cell activation, and resulted in improved abilities to stimulate HIV-1-specific CD8 T
cells. As such, our data demonstrate that type I IFN responses to HIV-1 in cDCs may play an
important role in the network of immune defense mechanisms in elite controllers, and delin-
eate specific connections between innate HIV-1 immune recognition and the generation of
adaptive immune responses in this specific patient population.
Dendritic cells represent a relatively hostile environment for HIV-1 and do not effectively
support HIV-1 replication steps, likely due to specific myeloid host proteins that effectively
block HIV-1 replication steps. SAMHD1 is one of the most prominent myeloid restriction fac-
tors, and can effectively inhibit HIV-1 reverse transcription by hydrolyzing dNTPs, which are
typically only available in limited amounts in resting myeloid cells. Despite evidence that
SAMHD1 sequences have been under positive selection pressure [51], it is interesting that
HIV-1 has not developed effective measures to counteract the antiviral activity of this host fac-
tor, suggesting that this protein may not significantly impair the ability of HIV-1 to establish a
long-lasting, progressive infection of the host. Our study demonstrates the paradoxical finding
that cDCs from EC are more permissive to early steps of HIV-1 replication while cDCs from
patients with progressive infection are more resistant to HIV-1 infection. This corresponded to
our observation that upregulation of SAMHD1 in response to HIV-1 was lower in EC, leading
to more efficient reverse transcription in cDCs from these patients. Whether this reduced in-
duction of SAMHD1 in cDC from EC represents a constitutive, cell-intrinsic aspect of cDC
from these patients, or occurs as a result of specific interactions with other cell types [52] is
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uncertain at present and requires further investigation. Overall, these data suggest that the
SAMHD1-dependent restriction of HIV-1 replication in cDCs benefits the virus more than the
host, and that a higher susceptibility of cDCs to HIV-1 paradoxically allows for more effective
systemic immune defense against HIV-1. Notably, ISG expression and levels of IFNα/β expres-
sion prior to ex-vivo infection with HIV-1 tended to be elevated in cDC from CP, consistent
with higher levels of immune activation in this cohort; it is possible that this increased baseline
immune activation may make cDC from these patients refractory to HIV-1-induced cell-in-
trinsic immune responses.
Cell-intrinsic immune responses in cDCs from EC in our study appeared to be facilitated by
an accumulation of reverse transcripts. These viral products seem to represent the main viral
substrate that is responsible for the induction of cellular type I IFN responses, as pharmacologi-
cal inhibition of viral reverse transcripts almost completely inhibited cell-intrinsic IFN-I secre-
tion, while inhibition of HIV-1 integration did not. These observations support previous data
suggesting that single-stranded HIV-1 DNA transcripts represent the predominant HIV-1 rep-
lication product that cell-intrinsic microbial sensors recognize [27,53]. The exact reasons re-
sponsible for the accumulation of reverse transcripts in EC are not entirely clear; however,
relative to the levels of reverse transcripts, HIV-1 integration in cDCs from EC was dispropor-
tionately reduced, and the ratio of reverse transcripts to integrated HIV-1 DNA was exceeding-
ly higher in cDCs from EC compared to all other patient cohorts. Together these data suggest
that cDCs from EC preferentially support a form of abortive HIV-1 infection that progresses
effectively through reverse transcription, but is restricted at the level of viral integration, possi-
bly through as of yet undefined host factors. Notably, prior studies found evidence for restric-
tion of HIV-1 integration in resting CD4+ T cells from EC [54], although the underlying
reason remained uncertain. The weak induction of host factors required for HIV-1 integration
in cDCs from EC, such as LEDGF/p75, may represent one important aspect contributing to the
accumulation of RT products in cDCs from EC, but a closer analysis of molecular mechanisms
regulating and possibly restricting HIV-1 integration in cDCs from EC will likely be highly in-
formative. In addition, it is interesting that higher levels of integrated HIV-1 DNA in CP and
HAART-treated patients did not translate in higher levels of HIV-1 mRNA transcription, as
determined by GFP expression; this suggests that additional restriction at the level of viral gene
transcription may be operational in these patients.
An important aspect of this work is the identification of cGAS as a critical factor for the gen-
eration of cell-intrinsic type I IFN responses in primary cDCs. cGAS can act as a cytosolic mi-
crobial DNA sensor that induces interferon secretion by production of the second messenger
cGAMP [43,55,56] and can play an important role for innate recognition of HIV-1 DNA in
myeloid cells [42]. However, in prior studies, cGAS-dependent immune recognition of HIV-1
was mostly analyzed in monocyte-derived DCs, which are highly resistant to HIV-1 unless co-
transfected with viral inhibitors of SAMHD1 [27]. Our experiments in more physiologic pri-
mary cDCs from EC demonstrated that HIV-1 infection led to a rapid induction of cGAS ex-
pression, and cGAS silencing in primary cDCs effectively inhibited type I IFN secretion. As
such, our work strongly suggests that cGAS can sense HIV-1 DNA under physiologically rele-
vant conditions, and that a more rapid induction of cGAS expression facilitates the generation
of cell-intrinsic type I IFN secretion in cDCs from EC. Notably, STING, an adaptor molecule
that acts downstream of cGAS-dependent immune recognition [43,57], also tended to be more
effectively induced in cDCs from EC, suggesting combined activity of the cGAS/STING path-
way for HIV-1 immune recognition in these patients. Interestingly, IFI16, which can act as a
cellular sensor for HIV-1 DNA in lymphoid CD4+ T cells and induces pyroptosis after abortive
infection with HIV-1 [45], was similarly induced in cDCs from all cohorts early after infection,
and therefore unlikely to be responsible for the early type I IFN responses observed in EC.
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While the role of highly-functional HIV-1-specific CD8 T cells for HIV-1 immune defense
in elite controllers is supported by a large number of studies [58–61], the ontogeny of these ef-
fective immune responses still remains largely obscure. Our data suggest that more efficient
cell-intrinsic responses against HIV-1 in cDCs from EC translate into an enhanced ability to
stimulate HIV-1-specific T cell responses. This may correspond to prior description to specific
expression patterns of immunoregulatory receptors on cDC from EC [62]. As such, more effec-
tive cell-intrinsic IFN secretion in cDCs may represent a distinguishing feature of elite control-
lers, and a key mechanism supporting the evolution of effective adaptive cellular immune
responses. Yet, growing evidence suggests that the ability of elite controllers to maintain unde-
tectable levels of viral replication is associated with increased levels of immune activation
[63,64], which may put patients at risk for higher frequencies of cardiovascular events and ac-
celerated immune aging. Therefore, it is tempting to speculate that improved abilities for cyto-
solic microbial immune recognition may represent a constitutive characteristic of ECs that
predisposes them for more potent immune activity against HIV-1, at the expense of elevated
generalized levels of immune activation. An improved understanding of interactions between
innate immune recognition in cDCs, immune activation and the evolution of adaptive CD8 T
cell responses in elite controllers will therefore be necessary for designing clinical strategies
aiming at inducing an elite controller-like phenotype in broader populations of HIV-1
patients.
Materials and Methods
Study participants
HIV-1 elite controllers who had maintained undetectable levels of HIV-1 replication for a me-
dian of 5 years (range 2–14) in the absence of antiretroviral therapy (EC, n = 26, median VL:
<49 copies/ml, median CD4 T cell counts: 835 cells/μl, range 444–2459 cells/μl), untreated
chronic progressors (CP, n = 26, median VL: 9010 copies/ml, range 1360–111000; median
CD4 T cell counts: 471 cells/μl, range 149–1098 cells/μl), HAART-treated chronically HIV-
1-infected patients with suppressed HIV-1 viremia (HAART, n = 23, median VL:<49 copies/
ml; median CD4 T cell counts: 710 cells/μl, range 109–1325 cells/μl) and HIV-1 seronegative
healthy persons (Neg, n = 26), were recruited for this study.
Ethics statement
All subjects gave written informed consent and the study was approved by the Institutional Re-
view Board of Massachusetts General Hospital/Partners Healthcare.
Viruses and constructs
GFP-encoding R5-tropic Ba-L HIV-1 viruses and GFP-encoding Δenv NL4-3 HIV-1 viruses
pseudotyped with vesicular stomatitis virus G envelope protein (VSV-G) [27,65,66], were
kindly provided by Dr. Dan Littman (New York University, New York, New York, USA).
Viral particles were produced by transfecting 293T cells with the respective HIV-1 plasmids
and, if applicable, with pCG-VSV-G, using TransIT-293 (Mirus) in OptiMEM per the manu-
facturer’s instructions. For control purposes, 293T cells were also transfected with Salmon
Sperm DNA solution (Invitrogen). Supernatants were harvested 48 hours after transfection,
centrifuged, filtered and treated with DNase I (20 U/ml) at room temperature for 1 hour, and
stored at −80°C.
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Isolation and purification of DC
BDCA1+ cDCs were purified from total PBMC suspensions by MACS using anti-human
BDCA-1 Kit and MS and LD columns (Miltenyi Biotec) (purity> 90%) for subsequent
analysis.
Ex-vivo infection assays and cell culture
PBMC or isolated cDC, without prior in vitro culture with activating agents, were infected with
GFP-encoding VSV-G peudotyped HIV-1 virus (MOI = 2.4) or R5-tropic HIV-1 (Ba-L,
MOI = 0.4) for 2 or 4 hours, respectively, at 37°C in the presence of 5μg/ml Polybrene (Sigma).
Cells cultured with media only or with 2μg/ml TLR3 ligand Poly (I:C) were used as negative or
positive control, respectively. Where indicated, PBMCs were cultured in the presence of 30ng/
ml IFNβ (PeproTech). After two washes, cells were plated at 5×105 cells per well in a 24-well
plate. Where indicated, the infection assays were performed in the presence of 50nM AZT or
100nM Efavirenz or 30μMRaltegavir to specifically block generation of either early or late
HIV-1 RT-products or integration, respectively. All antiretroviral agents were obtained from
the NIH AIDS Reagent Program (https://www.aidsreagent.org/program_info.cfm). In addi-
tion, monocyte derived dendritic cells were generated as previously described [62,67] and ana-
lyzed similarly after infection with HIV-1 for control purposes.
Gene expression analysis
cDNA was synthesized from total RNA obtained from purified BDCA1+ cDCs using themir-
Vana Isolation Kit (Life Technologies). Subsequently, expression of selected gene transcripts
(IFNα/β, SAMHD1, TREX1, TPNO3 and LEDGF/p75) was analyzed by semiquantitative PCR
using the Taqman gene expression assay (Life Technologies) with standardized primers/
probes, and normalized to the expression of the housekeeping gene ACTB (encoding β-actin).
In addition, expression of 28 interferon-stimulated genes (ISG) and 3 intracellular DNA sen-
sors (cGAS, STING, IFI16) was analyzed using customized 96-well plate TaqMan gene expres-
sion assays (Life Technologies) using a ViiA 7 instrument (Life Technologies).
Flow cytometry
At 24, 48 and 96 hours post-infection, PBMC were stained with LIVE/DEAD cell blue viability
dye (Invitrogen, Carlsbad, CA) and monoclonal antibodies directed against CD11c (Biole-
gend), CD14 (BD), CD40, CD83, CD86, HLA-DR (Biolegend), and BDCA-1 (Miltenyi Biotec)
and subsequently analyzed on a Fortessa cytometer (BD Biosciences, San Jose, CA). For intra-
cellular cytokine staining, cells were treated with a commercial fixation/permeabilization kit
(BioLegend) according to the manufacturer’s protocol. Data were analyzed with FlowJo soft-
ware (Tree Star). cDCs were identified from bulk PBMCs as a population of viable CD14- lym-
phocytes expressing high levels of CD11c and HLA-DR and the cDC specific marker BDCA-1.
Analysis of HIV-1 replication products
Early and late HIV-1 reverse transcripts and 2-LTR circles were amplified from cell lysates as
previously described [68]. Integrated HIV-1 DNA was determined using nested PCR with Alu-
LTR primers as previously described [54,65,69]. Copy numbers of reverse transcripts and inte-
grated HIV-1 DNA were obtained after extrapolation to specific standard curves generated
from HIV-1-infected 293T cells (kindly provided by Dr. Bushman, University of Pennsylva-
nia). qPCR data were normalized to relative CCR5 gene copy number. To determine the
amounts of de novo integrated HIV-1 DNA and 2-LTR circles in our ex vivo infection assays,
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raw qPCR data were corrected to the basal levels present in cDCs from each corresponding
subject. Determination of 2-LTR circle copy numbers were calculated by extrapolating qPCR
values to a standard curve generated using a plasmid harboring the sequence of 2-LTR junction
and the CCR5 gene (kindly provided by Dr. Mario Stevenson, University of Miami, FL) [54].
Western blot
Isolated cDCs from indicated study cohorts were lysed in RIPA buffer (Thermo Scientific) sup-
plemented with Halt Protease and Phosphatase inhibitors (Thermo Scientific). Lysates were
normalized for protein concentration using a Bradford assay (Bio-Rad), separated by
SDS-PAGE in 4–12% Tris-Glycine gels (Novex, Life Technologies) and transferred to a PVDF
membrane using the iBlot Gel Transfer system (Novex, Life Technologies). Membranes were
then blocked for 30min at room temperature using Odyssey Blocking buffer (LI-COR Biosci-
ences) and incubated with 1:1000 dilutions of anti-mouse β-Actin (Abcam) and either mouse
anti-SAMHD1 (Clone 1F6, Origene) or rabbit anti-cGAS antibodies (clone MB21D1, Sigma),
followed by secondary hybridization with goat anti-mouse (clone IRDye 800cW) and goat
anti-rabbit (clone IRDye 680RD) antibodies (Odyssey). The blots were visualized using an Od-
yssey imaging system (LI-COR) and the bands were quantified and normalized to β-Actin lev-
els using Image Studio 3.1 software (LI-COR).
siRNA-mediated gene knockdown
Knockdown of the DNA sensor cGAS and the restriction factor SAMHD1 were performed by
nucleofection of primary cDC (program FF137, Amaxa 4D-Nucleofector, Lonza) with specific
or scramble siRNAs (Thermo scientific) according to the manufacturer’s instructions. Nucleo-
fected cDC were infected with VSV-G-pseudotyped HIV-1 after 16 hours, type I IFN responses
and HIV-1 reverse transcripts were subsequently analyzed at 24 hours p.i. by qPCR. Efficiency
of siRNA-mediated knockdown was confirmed at the mRNA and protein levels by qPCR and
Western blot, respectively (Fig 4 and S5 Fig).
Mixed leukocyte reaction assays
PBMC were cultured in the presence of media or VSV-G-pseudotyped HIV-1 in the absence or
presence of described concentrations of AZT or EFV or Raltegavir for 24 hours. Afterwards,
BDCA1+ cDCs were purified by immunomagnetic enrichment and mixed with allogeneic total
peripheral blood T lymphocytes previously stained with 5μM carboxyfluorescein succinimidyl
ester (CFSE; Invitrogen) at a T:DC ratio of 4:1. As a control, T cells were also cultured in the
presence of media only or 2.5μg/ml PHA and 50IU/ml IL-2. After incubation for 6 days, cells
were washed, stained with viability dye and anti-CD4 and anti-CD8 antibodies (Biolegend, San
Diego, CA), and CFSE dilution on CD4 and CD8 T cell subpopulations was analyzed by flow
cytometry using a Fortessa flow cytometer.
In vitro stimulation of HIV-1 specific T cell responses
PBMC from HLA02:01+ individuals were cultured in the presence of media or VSV-G-HIV-1
for 48 hours. Subsequently, BDCA1+ cDCs were isolated as previously described and co-cul-
tured with a CD8+ T cell clone specific for the HLA02:01 restricted gag peptide SL9 (SLYNT-
VATL) at a T:DC ratio of 4:1. After 1 hour of initial incubation, cells were cultured for
additional 16 hours in the presence of Brefeldin A (BioLegend) and Monensin (Golgi Stop; BD
Biosciences). Subsequently, intracellular expression of IFNγ (BioLegend, San Diego, CA) in
the CD8 T cell clone was analyzed by flow cytometry after intracellular cytokine staining.
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Statistical analysis
Significance of phenotypic differences between the different patient cohorts were assessed
using MannWhitney U tests or Wilcoxon matched-pairs signed-rank test. When appropriate,
statistical analysis was corrected for multiple comparisons using a Kruskal-Wallis test with
post-hoc Dunn’s test or the Bonferroni correction. To investigate expression patterns of ISGs,
we used unsupervised complete linkage hierarchical cluster analysis, which groups samples to-
gether by the expression similarity, and gene coexpression network analysis, which identifies
the co-expression relationships among genes from different patient cohorts, by Pearson’s cor-
relation coefficients [70].
Supporting Information
S1 Fig. Expression of costimulatory molecules in cDCs from EC after ex-vivo infection with
HIV-1. (A): Representative flow cytometry histograms reflecting CD86 (upper panel), CD83
(middle panel) and CD40 surface expression (lower panel) of cDCs from HIV-negative persons
(Neg), individuals with chronic progressive HIV-1 infection (CP), Elite controllers (EC) and
HAART-treated HIV-1 patients (HAART) 24h after exposure to media (full grey histograms),
HIV-1 (blue histograms) or Poly I:C (purple histograms). Black histograms represent back-
ground levels for each marker defined by FMO controls. (B): Mean Fluorescence Intensity
(MFI) values of surface expression of CD86, CD83 and CD40 on cDCs from the different study
cohorts 24h (upper panels) or 48h (lower panels) after exposure to media only (Med), HIV-1
(HIV) or to the TLR3 ligand poly(I:C) (PIC). Data on plots represent raw MFI values. Differ-
ences within and between study cohorts were tested for statistical significance using Wilcoxon
matched-pairs signed rank test and MannWhitney test, respectively. Horizontal lines represent
the median for each specific cohort and experimental condition. Bonferroni correction was
used for multiple comparisons;  p<0.05;  p<0.01. (C): MFI values of surface expression of
CD86, CD83 and CD40 on HIV negative cDCs after 24h in culture of media (Med) or the indi-
cated concentrations of IFNβ. The plots correspond to a single experiment. (D): MFI values of
surface expression of CD86, CD83 and CD40 on cDCs from the different study cohorts after
24h of culture in media only (Med) or supplemented with 30ng/ml of IFNβ. Plots represent the
summary of n = 3 independent experiments. Horizontal lines represent mean values.
(EPS)
S2 Fig. Susceptibility of MDDCs and primary cDCs to ex vivo infection with VSV-G-pseu-
dotyped or R5-tropic HIV-1. (A): Flow cytometry plots showing proportions of GFP+ MDDC
at 24, 48 and 96 hours after exposure to GFP-encoding VSV-G-pseudotyped HIV-1. Numbers
in plots indicate the percentage of GFP+ cells. One representative experiment out of four is
shown. (B–C): Proportions (B) and GFP MFI (C) of GFP+ primary cDCs from indicated study
cohorts 96 hours after exposure to R5-tropic HIV-1 virus. Horizontal lines represent the medi-
an for each specific cohort and experimental condition. Differences were tested for statistical
significance using a Kruskal Wallis test with post-hoc Dunn’s test ( p<0.01;  p<0.001) or
using MannWhitney U test (# p<0.05; ## p<0.01). (D): Proportions of cDCs contained in
CD14- lymphocytes from Neg, CP, EC and HAART after 96h of infection with a VSV-G-pseu-
dotyped GFP-enconding HIV-1 virus.
(EPS)
S3 Fig. Rapid accumulation of HIV-1 RT products in cDC from EC.Detection of early and
late HIV-1 reverse transcripts (RT) in cDCs from healthy individuals (Neg, blue), HIV-1+
chronically infected persons (CP, orange), elite controllers (EC, green) and patients undergoing
anti-retroviral therapy (HAART, purple) at 24 hours after ex vivo infection with HIV-1.
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Horizontal lines represent the median for each specific cohort and experimental condition. Dif-
ferences were tested for statistical significance using a Kruskal Wallis test with post-hoc
Dunn’s test ( p<0.05;  p<0.01) or using MannWhitney U test (# p<0.05).
(EPS)
S4 Fig. SAMHD1 protein levels in primary cDCs from different study cohorts.Western blot
analysis of SAMHD1 (upper panel) and β-Actin (lower panel) protein levels in isolated
BDCA1+ cDCs from HIV-negative persons (Neg), individuals with chronic progressive HIV-1
infection (CP), Elite controllers (EC) 48h after exposure to medium (Med), HIV-1 (HIV-1) or
Poly I:C (P.I:C). (A) shows results from representative patients from different experiments, (B)
summarizes cumulative data from n = 5 study subjects from each cohort.
(EPS)
S5 Fig. cGAS is required to induce type I IFN responses in primary cDCs. (A): Spearman
correlations between induction of IFNβ expression and induction of cGAS (left) and STING
(right) expression levels in cDCs 48 hours after exposure to HIV-1. (B): Flow cytometry analy-
sis of viability on primary cDCs 24h after nucleofection with scramble- (SC) or cGAS-specific
(cGAS) siRNA. Numbers of dot plots represent the percentage of viable CD11c-positive viabili-
ty dye-negative DCs. (C): Efficacy of siRNA-mediated knockdown of cGAS expression in pri-
mary cDC. Data indicate mRNA (left panel) and protein (right panel) expression levels of
cGAS in cDCs nucleofected with scramble- (SC) or cGAS-specific siRNAs. Relative inhibition
of cGAS mRNA expression after knockdown is indicated. ( p<0.05, Wilcoxon matched-pairs
signed rank test). (D): IFNβmRNA levels present on cDCs nucleofected with SC- or cGAS-spe-
cific siRNAs and cultured in the presence of media (Med) or Poly I:C (PIC). Horizontal lines
represent the median for each specific cohort and experimental condition.
(EPS)
S1 Table. Fold change in expression of 28 ISGs in cDCs after HIV-1 infection.
(DOCX)
S2 Table. Basal levels of 28 ISGs in cDCs from EC and CP.
(DOC)
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